Anew research has established that, a willingly and cheaply obtainable malaria drug may help treat a wide range of cancers, counting lung, bowel, brain, and head and neck cancer. Enthused by the talented results in mice, the investigators have at present commenced testing the effects of the medicine on humans. ‘This is an exciting result. Lead author Gillies McKenna from Cancer Research UK Radiation Research Centre in Oxford has conveyed that, we have now started a clinical trial in Oxford to see if we can show the similar results in cancer patients. Gillies McKennahas also further conveyed that, we hope that this obtainable low cost drug will mean that resistant tumours can be re-sensitised to radiotherapy. The research looked at the consequence of the drug, called atovaquone, on tumours with short oxygen levels in mice to see if it could be repurposed to treat cancer.
This drug is no longer patented and is willingly and inexpensively obtainable from generic medicines manufacturers. This study established that the anti-malaria drug sluggish down the rate at which cancer cells use oxygen by targeting the mitochondria, the powerhouses of the cell that make energy, a process that uses oxygen. By sluggish down the use of oxygen, this drug back the low-oxygen levels in nearly all of the tumours. The fully-oxygenated tumours are more simply destroyed by radiotherapy. Emma Smith, Cancer Research UK’s Science Information Manager has also further conveyed in a statement that, the types of cancer that tend to have oxygen deprived regions are often additional dissimilar to treat – such as lung, bowel, brain and head and neck cancer. Smith has also further conveyed that, clinical trials will tell us whether this drug could help get better treatment options for patients with these types of tumour.